Article (Scientific journals)
Identification of isoAsp7-Aβ as a major Aβ variant in Alzheimer's disease, dementia with Lewy bodies and vascular dementia.
Schrempel, Sarah; Kottwitz, Anna Katharina; Piechotta, Anke et al.
2024In Acta Neuropathologica, 148 (1), p. 78
Peer Reviewed verified by ORBi
 

Files


Full Text
Identification of isoAsp7‑Aβ as a major Aβ variant in Alzheimer’s.pdf
Author postprint (8.63 MB)
Download

All documents in ORBilu are protected by a user license.

Send to



Details



Keywords :
Abeta; Alzheimer’s disease; Amyloid-β; Automated histology quantification; Dementia with Lewy bodies; Mini Mental State Examination; Post-translational modifications; Vascular dementia; Amyloid beta-Peptides; Isoaspartic Acid; Humans; Male; Female; Aged; Aged, 80 and over; Middle Aged; Brain/pathology; Brain/metabolism; Isoaspartic Acid/metabolism; Protein Processing, Post-Translational; Alzheimer Disease/pathology; Alzheimer Disease/genetics; Alzheimer Disease/metabolism; Amyloid beta-Peptides/metabolism; Lewy Body Disease/pathology; Lewy Body Disease/metabolism; Lewy Body Disease/genetics; Dementia, Vascular/pathology; Dementia, Vascular/metabolism; Brain; Dementia, Vascular; Lewy Body Disease; Pathology and Forensic Medicine; Neurology (clinical); Cellular and Molecular Neuroscience; Amyloid-beta
Abstract :
[en] The formation of amyloid-β (Aβ) aggregates in brain is a neuropathological hallmark of Alzheimer's disease (AD). However, there is mounting evidence that Aβ also plays a pathogenic role in other types of dementia and that specific post-translational Aβ modifications contribute to its pathogenic profile. The objective of this study was to test the hypothesis that distinct types of dementia are characterized by specific patterns of post-translationally modified Aβ variants. We conducted a comparative analysis and quantified Aβ as well as Aβ with pyroglutamate (pGlu3-Aβ and pGlu11-Aβ), N-truncation (Aβ(4-X)), isoaspartate racemization (isoAsp7-Aβ and isoAsp27-Aβ), phosphorylation (pSer8-Aβ and pSer26-Aβ) or nitration (3NTyr10-Aβ) modification in post mortem human brain tissue from non-demented control subjects in comparison to tissue classified as pre-symptomatic AD (Pre-AD), AD, dementia with Lewy bodies and vascular dementia. Aβ modification-specific immunohistochemical labelings of brain sections from the posterior superior temporal gyrus were examined by machine learning-based segmentation protocols and immunoassay analyses in brain tissue after sequential Aβ extraction were carried out. Our findings revealed that AD cases displayed the highest concentrations of all Aβ variants followed by dementia with Lewy bodies, Pre-AD, vascular dementia and non-demented controls. With both analytical methods, we identified the isoAsp7-Aβ variant as a highly abundant Aβ form in all clinical conditions, followed by Aβ(4-X), pGlu3-Aβ, pGlu11-Aβ and pSer8-Aβ. These Aβ variants were detected in distinct plaque types of compact, coarse-grained, cored and diffuse morphologies and, with varying frequencies, in cerebral blood vessels. The 3NTyr10-Aβ, pSer26-Aβ and isoAsp27-Aβ variants were not found to be present in Aβ plaques but were detected intraneuronally. There was a strong positive correlation between isoAsp7-Aβ and Thal phase and a moderate negative correlation between isoAsp7-Aβ and performance on the Mini Mental State Examination. Furthermore, the abundance of all Aβ variants was highest in APOE 3/4 carriers. In aggregation assays, the isoAsp7-Aβ, pGlu3-Aβ and pGlu11-Aβ variants showed instant fibril formation without lag phase, whereas Aβ(4-X), pSer26-Aβ and isoAsp27-Aβ did not form fibrils. We conclude that targeting Aβ post-translational modifications, and in particular the highly abundant isoAsp7-Aβ variant, might be considered for diagnostic and therapeutic approaches in different types of dementia. Hence, our findings might have implications for current antibody-based therapies of AD.
Disciplines :
Neurology
Author, co-author :
Schrempel, Sarah ;  Paul Flechsig Institute - Centre of Neuropathology and Brain Research, University of Leipzig, Liebigstraße 19, 04103, Leipzig, Germany
Kottwitz, Anna Katharina ;  Department of Molecular Drug Design and Target Validation, Fraunhofer Institute for Cell Therapy and Immunology, 06120, Halle (Saale), Germany ; Center for Natural Product-based Therapeutics, Anhalt University of Applied Sciences, 06366, Köthen, Germany
Piechotta, Anke;  Department of Molecular Drug Design and Target Validation, Fraunhofer Institute for Cell Therapy and Immunology, 06120, Halle (Saale), Germany
Gnoth, Kathrin;  Department of Molecular Drug Design and Target Validation, Fraunhofer Institute for Cell Therapy and Immunology, 06120, Halle (Saale), Germany ; Center for Natural Product-based Therapeutics, Anhalt University of Applied Sciences, 06366, Köthen, Germany
Büschgens, Luca;  Department of Psychiatry and Psychotherapy, University Medical Center Göttingen, Georg-August-University, 37075, Göttingen, Germany
Hartlage-Rübsamen, Maike;  Paul Flechsig Institute - Centre of Neuropathology and Brain Research, University of Leipzig, Liebigstraße 19, 04103, Leipzig, Germany
Morawski, Markus;  Paul Flechsig Institute - Centre of Neuropathology and Brain Research, University of Leipzig, Liebigstraße 19, 04103, Leipzig, Germany
Schenk, Mathias;  Department of Molecular Drug Design and Target Validation, Fraunhofer Institute for Cell Therapy and Immunology, 06120, Halle (Saale), Germany
Kleinschmidt, Martin;  Department of Molecular Drug Design and Target Validation, Fraunhofer Institute for Cell Therapy and Immunology, 06120, Halle (Saale), Germany
Serrano, Geidy E;  Civin Laboratory for Neuropathology, Brain and Body Donation Program, Banner Sun Health Research Institute, 10515 W Santa Fe Drive, Sun City, AZ, 85351, USA
Beach, Thomas G;  Civin Laboratory for Neuropathology, Brain and Body Donation Program, Banner Sun Health Research Institute, 10515 W Santa Fe Drive, Sun City, AZ, 85351, USA
Rostagno, Agueda;  Department of Pathology, New York University School of Medicine, New York, NY, USA
Ghiso, Jorge;  Department of Pathology, New York University School of Medicine, New York, NY, USA
HENEKA, Michael  ;  University of Luxembourg > Luxembourg Centre for Systems Biomedicine (LCSB)
Walter, Jochen;  Center of Neurology, Molecular Cell Biology, University Hospital Bonn, 53127, Bonn, Germany
Wirths, Oliver;  Department of Psychiatry and Psychotherapy, University Medical Center Göttingen, Georg-August-University, 37075, Göttingen, Germany
Schilling, Stephan;  Department of Molecular Drug Design and Target Validation, Fraunhofer Institute for Cell Therapy and Immunology, 06120, Halle (Saale), Germany ; Center for Natural Product-based Therapeutics, Anhalt University of Applied Sciences, 06366, Köthen, Germany
Roßner, Steffen;  Paul Flechsig Institute - Centre of Neuropathology and Brain Research, University of Leipzig, Liebigstraße 19, 04103, Leipzig, Germany. steffen.rossner@medizin.uni-leipzig.de
More authors (8 more) Less
External co-authors :
yes
Language :
English
Title :
Identification of isoAsp7-Aβ as a major Aβ variant in Alzheimer's disease, dementia with Lewy bodies and vascular dementia.
Publication date :
03 December 2024
Journal title :
Acta Neuropathologica
ISSN :
0001-6322
eISSN :
1432-0533
Publisher :
Springer Science and Business Media Deutschland GmbH, Germany
Volume :
148
Issue :
1
Pages :
78
Peer reviewed :
Peer Reviewed verified by ORBi
Funders :
Federal State of Saxony
Federal State of Saxony-Anhalt
National Institute of Neurological Disorders and Stroke
National Institute on Aging
Arizona Department of Health Services
Arizona Biomedical Research Commission
Michael J. Fox Foundation for Parkinson’s Research
German Research Foundation
Universität Leipzig
Funding text :
We are grateful to the Arizona Study of Aging and Neurodegenerative Disorders and Brain and Body Donation Program for the provision of human brain tissue. The Program has been supported by the National Institute of Neurological Disorders and Stroke (U24 NS072026, National Brain and Tissue Resource for Parkinson\u2019s Disease and Related Disorders), the National Institute on Aging (P30AG019610 and P30AG072980, Arizona Alzheimer\u2019s Disease Core Center), the Arizona Department of Health Services (contract 211002, Arizona Alzheimer\u2019s Research Center), the Arizona Biomedical Research Commission (contracts 4001, 0011, 05-901 and 1001 to the Arizona Parkinson's Disease Consortium) and the Michael J. Fox Foundation for Parkinson\u2019s Research. This work was also supported by the German Research Foundation (DFG grants RO 2226/17-1 to S.R.; WA1477/6-6 to J.W. and SCHI 1437/4-1 to St.S.; GRK2824 and WI 3472/11-1 to O.W.). Sa.S. received a PhD student fellowship awarded by the Federal State of Saxony. A.K.K. received a PhD student fellowship awarded by the Federal State of Saxony-Anhalt. We thank S. Theil for hybridoma cell culture and purification of antibodies (1E4E11 and 5H11C10).Open Access funding enabled and organized by Projekt DEAL. Federal State of Saxony, Fellowship Sarah Schrempel, Federal State of Saxony-Anhalt, Fellowship Anna Katharina Kottwitz, National Institute of Neurological Disorders and Stroke, U24 NS072026, National Institute on Aging, P30AG019610 and P30AG072980, Arizona Department of Health Services, contract 211002, Arizona Biomedical Research Commission, contracts 4001, 0011, 05-901 and 1001, Michael J. Fox Foundation for Parkinson\u2019s Research, German Research Foundation, WA 1477/6-6, GRK2824, WI 3472/11-1, SCHI 1437/4-1, RO 2226/17-1.
Available on ORBilu :
since 23 January 2026

Statistics


Number of views
4 (0 by Unilu)
Number of downloads
0 (0 by Unilu)

Scopus citations®
 
6
Scopus citations®
without self-citations
6
OpenCitations
 
0
OpenAlex citations
 
12
WoS citations
 
5

Bibliography


Similar publications



Contact ORBilu